BioGaia AB (FRA:BGLA)
€ 9.115 -0.035 (-0.38%) Market Cap: 931.59 Mil Enterprise Value: 835.03 Mil PE Ratio: 31.83 PB Ratio: 6.64 GF Score: 95/100

Q4 2019 Biogaia AB Earnings Call Transcript

Feb 06, 2020 / 08:30AM GMT
Release Date Price: €8.15 (+1.24%)
Operator

Ladies and gentlemen, welcome to BioGaia Q4 report 2019. Today, I'm pleased to present Isabelle Ducellier, CEO. (Operator Instructions)

Isabelle, please begin.

Isabelle Valerie Ghislaine Ducellier;publ;CEO;President
BioGaia AB

()-&

Yes. Good morning, and thank you who follow BioGaia. So I'm going to present the last quarter of 2019, starting by saying that in terms of sales of our products, we had a good quarter with an increase of 6% of our product sales. Having said that, as everybody is well informed about, due to the loss of the GUM contract, royalty contract with Nestlé and the delays and problem with delivery with (inaudible) in Q4, the total sales have decreased by minus 1%.

If we look at the product sales more specifically, we are very happy about the last quarter for our Pediatrics portfolio that presented a very nice increase of 10%. In terms of specific SKUs, the Protectis drops against colic for kids has been showing a very good growth. And 2019 has been a very good year for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot